# HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07790510/  
OnCo record `nct07790510` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cetuximab, CAPOX, FLOT in colorectal cancer, run by Haisco Pharmaceutical Group Co., Ltd., now recruiting.

## Summary

HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT07790510 by Haisco Pharmaceutical Group Co., Ltd., with 180 participants planned, started 2026-08-12 and due to reach its primary completion in 2029-09-30. Interventions recorded: HSK42360-Na Tablets, Cetuximab (EGFR inhibitor), mFOLFOX6 Regimen (Oxaliplatin/Leucovorin/5-FU), FOLFIRI Regimen (Irinotecan/Leucovorin/5-FU). Conditions listed: Metastatic Colorectal Cancer (CRC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07790510
- Phase: 1/2
- Setting: A Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in Patients With BRAF V600-Mutant Metastatic Colorectal Cancer
- Sponsor: Haisco Pharmaceutical Group Co., Ltd.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07790510: https://clinicaltrials.gov/study/NCT07790510

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/)

---
JSON: https://onco.cc/api/v1/entities/nct07790510.json